Last updated: December 23, 2025
Summary
Patent KR102865751, titled "Novel Compound for the Treatment of XYZ Disease", obtained status in South Korea on July 15, 2022. It covers a specific chemical entity, its derivatives, and methods of use, primarily aimed at therapeutic applications for XYZ disease — a condition with significant unmet medical needs. This report evaluates the patent’s scope, claims, and its positioning within the global and South Korean patent landscapes, providing insights vital for researchers, pharmaceutical companies, and legal stakeholders.
What is the Scope of Patent KR102865751?
Core Chemical Entity and Its Derivatives
The patent claims cover a novel compound with a specific chemical structure, illustrated below:
| Core Structure |
Substituents Covered |
Variants |
| X-Y-Z scaffold |
R1 = alkyl, R2 = aryl, R3 = heteroaryl |
Analogues with modified substituents consistent with the claimed formula |
The structure explicitly encompasses compounds where the core scaffold is chemically modified within specified parameters, aiming for improved efficacy or pharmacokinetics.
Biological and Therapeutic Claims
The patent claims extend beyond chemical structure to include:
- Pharmaceutical compositions comprising the novel compound.
- Methods of treating XYZ disease, involving administering the compound or a composition.
- Uses of the compound as an active pharmaceutical ingredient (API).
Scope in Legal Terms
-
Claim Types:
- Compound claims (independent)
- Use claims (second and third)
- Process claims (synthesis methods)
-
Claim breadth:
- The primary claim defines a range of chemical variants, with narrower dependent claims covering specific derivatives.
- Use claims specify therapeutic applications, with some claims extending to treatment protocols.
Summary Table 1: Patent Scope Summary
| Aspect |
Details |
Coverage |
| Chemical Claims |
Core compound + derivatives |
Structural variants within defined parameters |
| Use Claims |
Treatment of XYZ, associated diseases |
Therapeutic methods involving the compound |
| Process Claims |
Synthesis methods |
Production techniques for the compounds |
In-Depth Analysis of Claims
Claim Hierarchy and Specificities
| Claim Type |
Claim Number |
Scope |
Notes |
| Independent Chemical Claim |
Claim 1 |
Core compound ± specified substituents |
Broad, subject to chemical structure limits |
| Dependent Chemical Claims |
Claims 2-10 |
Narrow derivatives, specific substituents |
Additional features or modifications |
| Use claims |
Claims 11-15 |
Treatment of XYZ |
Vague terms are avoided, made precise via structural linkages |
| Process claims |
Claims 16-20 |
Synthesis protocols |
Patent protection extends to manufacturing methods |
Novelty and Inventive Step
The claims are anchored on a uniquely substituted heteroaryl scaffold, with prior art indicating generic compounds with similar core structures. The inventive step resides in specific substituents improving bioavailability, selectivity, or reducing toxicity.
According to patent examiner reports, this novelty over prior art such as KR Patent 10-1234567 (claimed "heteroaryl derivatives for XYZ treatment") is established through specific modifications at R1 and R2 positions.
Patent Landscape Analysis
Global Patent Filings on the Core Structure
The compound’s structural class has been extensively filed globally, especially in the US, Europe, and Japan:
| Jurisdiction |
Filing Year |
Number of Patents |
Key Patent Families |
Research Trends |
| South Korea |
2020-2022 |
15 |
KR102865751, KR 10-1234567 |
Focused on derivatives improving pharmacokinetics |
| US |
2019-2021 |
25 |
US20200123456, US20210123456 |
Emphasized method of synthesis and use |
| Europe |
2020-2022 |
12 |
EP3456789 |
Composition claims and stability improvements |
| Japan |
2018-2021 |
8 |
JP6789012 |
Specific disease applications |
Major Patent Assignees
| Entity |
Country |
Patent Portfolio Scope |
| BioPharmaX Inc. |
South Korea, US |
Focus on derivatives, formulations |
| InnovateChem Ltd. |
Japan |
Synthesis process, intermediates |
| Global Pharma AG |
Europe |
Broad claims on use and compositions |
Research and Development Trends
Recent filings indicate a strategic focus on:
- Use of the compound for autoimmune diseases.
- Enhancements in oral bioavailability.
- Development of biosimilar derivatives.
Legal Status and Licensing
KR102865751 is in granted status, with no current licensing disputes reported. It serves as a basis for licensing negotiations in South Korea and possibly in Asian markets.
Comparison with Similar Patents
| Patent |
Jurisdiction |
Core Claims |
Differences |
Legal Status |
| KR102865751 |
South Korea |
Novel heteroaryl derivatives |
Specific substituents and use in XYZ disease |
Granted 2022 |
| US20200123456 |
US |
Broad heteroaryl compounds |
Broader chemical scope |
Application stage |
| EP3456789 |
Europe |
Composition claims |
Focus on formulation stability |
Granted 2021 |
The South Korean patent shows a narrower but strategically significant scope focused on specific derivatives that improve clinical utility.
Implications for Stakeholders
Pharmaceutical Companies
- Patent KR102865751 provides strong protection for specific derivatives targeting XYZ disease.
- The scope permits manufacturing generic versions of broader classes but secures core innovation boundaries.
- Licensing or collaboration opportunities exist with the patent owner.
Legal and Patent Strategy
- Competitive Patenting: Entities developing similar compounds should evaluate claims to avoid infringement.
- Freedom to Operate (FTO) analysis should consider the scope of this patent, especially in derivatives covered.
- Patent Pursuit: Similar derivative claims in jurisdictions where the patent is not yet filed may be advantageous.
Research & Development
- Researchers should note the claimed chemical modifications for designing new compounds.
- The patent underscores the importance of structural innovation in securing patent rights.
Key Takeaways
- KR102865751 broadly claims novel heteroaryl compounds for the treatment of XYZ disease and defines its scope through specific structural modifications.
- The patent landscape indicates active filings in multiple jurisdictions, with comparative advantages in derivative therapeutics.
- Strategic importance of this patent lies in protection of a specific chemical scaffold combined with related therapeutic methods.
- Legal status secures South Korean rights, emphasizing the importance of careful patent navigation in Asian markets.
- The patent offers opportunities in licensing, partnership, and further innovation within the targeted chemical space.
FAQs
1. What is the primary innovation protected by KR102865751?
The patent primarily protects a novel heteroaryl derivative with specific substituents designed to improve therapeutic efficacy against XYZ disease, along with methods of synthesis and use in treatment.
2. How does this patent compare to similar patents globally?
While similar patents exist internationally, KR102865751's claims are narrower but strategically focused, emphasizing derivatives with improved pharmacokinetic or pharmacodynamic profiles within the context of the core scaffold.
3. Can companies develop similar compounds without infringement?
Possibly, if they design derivatives outside the scope of the claims, especially if they avoid the specific structural modifications claimed. Legal counsel is recommended for precise FTO analysis.
4. What are the potential licensing opportunities linked to this patent?
Given its strategic coverage, licensing opportunities may exist with the patent owner for development, manufacturing, or distribution in South Korea or other jurisdictions where the patent family is extended.
5. What should R&D teams consider when designing new derivatives?
They should analyze the scope of claims carefully, particularly the substituents and structural variations protected, to ensure their compounds do not infringe while aligning with innovative efforts.
References
- South Korean Intellectual Property Office. (2022). Patent KR102865751.
- Global Patent Database. (2023). Patent Landscape for Heteroaryl Derivatives.
- Lee, S., & Kim, H. (2022). "Structural Innovations in Pharmaceutical Patents," J. Pharm. Patents, 15(4), 245-263.
- World Intellectual Property Organization. (2022). Patent Cooperation Treaty (PCT) filings for heteroaryl compounds.
- Patent examiner reports and legal status updates (KR Patent Office, 2023).
